journal
Journals Lancet. Gastroenterology & Hep...

Lancet. Gastroenterology & Hepatology

https://read.qxmd.com/read/38604192/has-the-time-come-for-a-systematic-top-down-approach-in-crohn-s-disease
#41
JOURNAL ARTICLE
Mathurin Fumery, Anthony Buisson
No abstract text is available yet for this article.
May 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38604191/addressing-the-evolving-landscape-of-global-malnutrition
#42
EDITORIAL
The Lancet Gastroenterology Hepatology
No abstract text is available yet for this article.
May 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38513683/mri-guided-stereotactic-ablative-body-radiotherapy-versus-ct-guided-percutaneous-irreversible-electroporation-for-locally-advanced-pancreatic-cancer-crossfire-a-single-centre-open-label-randomised-phase-2-trial
#43
RANDOMIZED CONTROLLED TRIAL
Florentine E F Timmer, Bart Geboers, Alette H Ruarus, Laurien G P H Vroomen, Evelien A C Schouten, Susan van der Lei, Danielle J W Vos, Madelon Dijkstra, Hannah H Schulz, Joyce Bakker, Bente A T van den Bemd, Petrousjka M van den Tol, Robbert S Puijk, Birgit I Lissenberg-Witte, Tanja D de Gruijl, Jan J J de Vries, Frank J Lagerwaard, Hester J Scheffer, Anna M E Bruynzeel, Martijn R Meijerink
BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible electroporation could enhance patient outcomes by extending survival while preserving quality of life...
May 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38499019/prophylactic-abdominal-drainage-after-distal-pancreatectomy-pandorina-an-international-multicentre-open-label-randomised-controlled-non-inferiority-trial
#44
RANDOMIZED CONTROLLED TRIAL
Eduard A van Bodegraven, Alberto Balduzzi, Tess M E van Ramshorst, Giuseppe Malleo, Frederique L Vissers, Jony van Hilst, Sebastiaan Festen, Mohammad Abu Hilal, Horacio J Asbun, Nynke Michiels, Bas Groot Koerkamp, Olivier R C Busch, Freek Daams, Misha D P Luyer, Marco Ramera, Giovanni Marchegiani, Joost M Klaase, I Quintus Molenaar, Matteo de Pastena, Gabriella Lionetto, Pier Giuseppe Vacca, Hjalmar C van Santvoort, Martijn W J Stommel, Daan J Lips, Mariëlle M E Coolsen, J Sven D Mieog, Roberto Salvia, Casper H J van Eijck, Marc G Besselink
BACKGROUND: Prophylactic passive abdominal drainage is standard practice after distal pancreatectomy. This approach aims to mitigate the consequences of postoperative pancreatic fistula (POPF) but its added value, especially in patients at low risk of POPF, is currently being debated. We aimed to assess the non-inferiority of a no-drain policy in patients after distal pancreatectomy. METHODS: In this international, multicentre, open-label, randomised controlled, non-inferiority trial, we recruited patients aged 18 years or older undergoing open or minimally invasive elective distal pancreatectomy for all indications in 12 centres in the Netherlands and Italy...
May 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460541/infinite-life
#45
JOURNAL ARTICLE
Joe Moody
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460540/you-are-what-you-eat-a-twin-experiment
#46
JOURNAL ARTICLE
Hollie Sherwood-Martin
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460538/gluten-and-non-coeliac-gluten-sensitivity-the-nocebo-effect-and-future-avenues-authors-reply
#47
LETTER
Marlijne C G de Graaf, Daniel Keszthelyi, Fred J P H Brouns, Louise Dye, Daisy M A E Jonkers
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460537/gluten-and-non-coeliac-gluten-sensitivity-the-nocebo-effect-and-future-avenues
#48
LETTER
Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460536/comprehensive-screening-for-superficial-oesophageal-squamous-cell-carcinoma-and-precancerous-lesions-authors-reply
#49
LETTER
Xiang-Lei Yuan, Bing Hu
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460535/comprehensive-screening-for-superficial-oesophageal-squamous-cell-carcinoma-and-precancerous-lesions
#50
LETTER
Daisuke Murakami, Masayuki Yamato, Takayoshi Nishino, Makoto Arai
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460534/the-destin-trial-to-step-up-or-not-authors-reply
#51
LETTER
Ji Young Bang, Shyam Varadarajulu
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460533/the-destin-trial-to-step-up-or-not
#52
LETTER
Oscar Cahyadi, Vinay Dhir, John Leeds, Enrique de-Madaria, Nadeem Tehami
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460532/the-destin-trial-to-step-up-or-not
#53
LETTER
Avinash Tiwari, Mayank Mehrotra, Ajmal Hasan, Jaya Agarwal, Gaurav Kumar Singh
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38460531/resmetirom-for-nash-balancing-promise-and-prudence
#54
EDITORIAL
The Lancet Gastroenterology Hepatology
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38367633/development-and-evaluation-of-a-simple-treatment-eligibility-score-hepsanet-to-decentralise-hepatitis-b-care-in-africa-a-cross-sectional-study
#55
JOURNAL ARTICLE
Nicolas Minier, Alice Nanelin Guingané, Edith Okeke, Edford Sinkala, Asgeir Johannessen, Monique I Andersson, Pantong Davwar, Hailemichael Desalegn, Mary Duguru, Fatou Fall, Souleyman Mboup, Tongai Maponga, Philippa C Matthews, Adrià Ramírez Mena, Gibril Ndow, Stian M S Orlien, Nicholas Riches, Moussa Seydi, Mark Sonderup, C Wendy Spearman, Alexander J Stockdale, Jantjie Taljaard, Michael Vinikoor, Gilles Wandeler, Maud Lemoine, Yusuke Shimakawa, Roger Sombié
BACKGROUND: Hepatitis B virus (HBV) elimination requires expanding and decentralising HBV care services. However, peripheral health facilities lack access to diagnostic tools to assess eligibility for antiviral therapy. Through the Hepatitis B in Africa Collaborative Network (HEPSANET), we aimed to develop and evaluate a score using tests generally available at lower-level facilities, to simplify the evaluation of antiviral therapy eligibility in people living with HBV. METHODS: We surveyed the availability of clinical and laboratory parameters across different health-care levels in sub-Saharan Africa...
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38364833/the-cosmic-312-study-will-it-shape-future-combination-therapies-for-advanced-hepatocellular-carcinoma
#56
JOURNAL ARTICLE
Anna Saborowski, Ana Lleo
No abstract text is available yet for this article.
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38364832/cabozantinib-plus-atezolizumab-versus-sorafenib-for-advanced-hepatocellular-carcinoma-cosmic-312-final-results-of-a-randomised-phase-3-study
#57
RANDOMIZED CONTROLLED TRIAL
Thomas Yau, Ahmed Kaseb, Ann-Lii Cheng, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa
BACKGROUND: The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following longer follow-up. METHODS: COSMIC-312 was an open-label, randomised, phase 3 study done across 178 centres in 32 countries...
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38301673/covered-versus-bare-metal-stenting-of-the-mesenteric-arteries-in-patients-with-chronic-mesenteric-ischaemia-cobagi-a-multicentre-patient-blinded-and-investigator-blinded-randomised-controlled-trial
#58
RANDOMIZED CONTROLLED TRIAL
Luke G Terlouw, Louisa J D van Dijk, Desirée van Noord, Olaf J Bakker, Diederik C Bijdevaate, Nicole S Erler, Bram Fioole, Jihan Harki, Daniel A F van den Heuvel, Jan Willem Hinnen, Jeroen J Kolkman, Suzan Nikkessen, André S van Petersen, Henk F M Smits, Hence J M Verhagen, Annemarie C de Vries, Jean-Paul P M de Vries, Dammis Vroegindeweij, Robert H Geelkerken, Marco J Bruno, Adriaan Moelker
BACKGROUND: Mesenteric artery stenting with a bare-metal stent is the current treatment for atherosclerotic chronic mesenteric ischaemia. Long-term patency of bare-metal stents is unsatisfactory due to in-stent intimal hyperplasia. Use of covered stents might improve long-term patency. We aimed to compare the patency of covered stents and bare-metal stents in patients with chronic mesenteric ischaemia. METHODS: We conducted a multicentre, patient-blinded and investigator-blinded, randomised controlled trial including patients with chronic mesenteric ischaemia undergoing mesenteric artery stenting...
April 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38340757/correction-to-lancet-gastroenterol-hepatol-2024-9-110-23
#59
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38340756/correction-to-lancet-gastroenterol-hepatol-2024-9-83-91
#60
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Lancet. Gastroenterology & Hepatology
journal
journal
53645
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.